___

• 1. World Health Organization, HIV/AIDS Department. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010: 90.
• 2. World Health Organization, HIV/AIDS Department. Strategic approaches to the prevention of HIV infection in infants: report of a WHO meeting, Morges. Switzerland: Geneva, 2002.
• 3. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection 2009; 91-2.
• 4. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338: 853-60.[Özet]
• 5. Brenner BG, Turner D, Wainberg MA. HIV-1 drug resistance: can we overcome? Expert Opin Biol Ther 2002;2: 751-61. [Özet]
• 6. Ait-Khaled M, Stone C, Amphlett G, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002;16(12): 1686-9. [Özet]
• 7. Lafeuillade A, Poggi C, Hittinger G, et al. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates. HIV Med 2001;2(4): 231-5. [Özet]
• 8. Millinkoviç A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2004;2(3): 367-73.